Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million ...
Morning Overview on MSN
One in nine older adults still faces a dangerous drug-interaction risk
Roughly one in nine Americans aged 65 and older is exposed to a prescription drug combination flagged as a major drug-drug ...
Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
Amyotrophic lateral sclerosis (ALS) received widespread attention in the summer of 2014 thanks to the Ice Bucket Challenge. Millions of people participated, drenching themselves in ice-cold water to ...
CNS metastases represent one of the most devastating complications of non-small-cell lung cancer (NSCLC), affecting up to 50% of patients during their ...
Axsome Therapeutics(NASDAQ: AXSM) has been going through a particularly significant growth phase in recent years, launching ...
AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s ...
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026Affirms 2026 guidance on key milestones Reports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results